Page last updated: 2024-09-02

fingolimod hydrochloride and Kussmaul Aphasia

fingolimod hydrochloride has been researched along with Kussmaul Aphasia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Altobelli, C; Anastasio, P; Barbarulo, AM; Conchiglia, G; D'Amico, A; Di Pietro, A; Fratta, M; Lus, G; Rossi, F; Signoriello, E; Ugga, L	1

Other Studies

1 other study(ies) available for fingolimod hydrochloride and Kussmaul Aphasia

Article	Year
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis. Multiple sclerosis and related disorders, 2020, Volume: 38 Topics: Adult; Alemtuzumab; Behavioral Symptoms; Brain Diseases; Brain Stem; Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Mutism; Recurrence; White Matter; Young Adult	2020

Article

Year

Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis.

Multiple sclerosis and related disorders, 2020, Volume: 38

Topics: Adult; Alemtuzumab; Behavioral Symptoms; Brain Diseases; Brain Stem; Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Mutism; Recurrence; White Matter; Young Adult

2020